De­ci­phera banks a $52M C round for can­cer R&D; Io­n­is adds $50M mile­stone from Bio­gen

→  Waltham, MA-based De­ci­phera Ther­a­peu­tics an­nounced that it has banked a $52 mil­lion C round to keep fu­el­ing its grow­ing pipeline ef­forts, in­clud­ing its lead drug, still in the ear­ly stages of de­vel­op­ment, a pan-KIT and PDGFR in­hibitor dubbed DCC-2618. Viking Glob­al In­vestors, Red­mile Group and Sphera Glob­al Health­care Fund led the round, joined by De­ci­phera’s ex­ist­ing in­vestors in­clud­ing New Leaf Ven­ture Part­ners. Said De­ci­phera CEO Michael Tay­lor: “The pro­ceeds of this fi­nanc­ing will be used to ad­vance de­vel­op­ment of DCC-2618 and DCC-3014 in­to lat­er-stage clin­i­cal tri­als with the goal of de­liv­er­ing new ther­a­pies that ad­dress key re­sis­tance mech­a­nisms to im­prove can­cer treat­ment out­comes.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER